Yumanity Therapeutics (Yumanity Therapeutics) Inventory Turnover : 0.00 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Yumanity Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2022 was $0.00 Mil. Yumanity Therapeutics's Average Total Inventories for the quarter that ended in Sep. 2022 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Yumanity Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 0.00.

Yumanity Therapeutics Inventory Turnover Historical Data

The historical data trend for Yumanity Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Inventory Turnover Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Inventory Turnover

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Inventory Turnover	Get a 7-Day Free Trial							-	-	-	-	-

Yumanity Therapeutics Inventory Turnover Calculation

Yumanity Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2021 is calculated as

	Inventory Turnover (A: Dec. 2021 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2021 )	/ (	(Total Inventories (A: Dec. 2020 )	+	Total Inventories (A: Dec. 2021 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Yumanity Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

	Inventory Turnover (Q: Sep. 2022 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Sep. 2022 )	/ (	(Total Inventories (Q: Jun. 2022 )	+	Total Inventories (Q: Sep. 2022 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Yumanity Therapeutics (NAS:YMTX) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Yumanity Therapeutics's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2022 )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Yumanity Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	0	/	1.402
	=	0.00

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Yumanity Therapeutics Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (Yumanity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (NAS:YMTX) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Executives

Shawn Iadonato	director, officer: Chief Executive Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips	officer: President	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Raymond J. Bartoszek	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker	officer: Chief Financial Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny	officer: General Counsel	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux	officer: Chief Scientific Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Richard Peters	director, officer: President & CEO	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Devin Whittemore Smith	officer: SVP and General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Marie Epstein	officer: Principal Accounting Officer	C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Michael D Wyzga	officer: See Remarks	C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Paulash Mohsen	officer: Chief Business Officer	C/O YUMANITY THERAPEUTICS, INC., 40 GUESS STREET SUITE 4410, BOSTON MA 02135
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma	officer: EVP, Head of R&D	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
N Anthony Coles	director, officer: Executive Chair	MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054